Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Update

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the recipient of a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 34,300 shares, a decline of 90.8% from the October 15th total of 374,300 shares. Based on an average daily volume of 202,400 shares, the days-to-cover ratio is currently 0.2 days.

Chugai Pharmaceutical Stock Performance

Shares of CHGCY traded down $0.50 during midday trading on Tuesday, hitting $23.55. The stock had a trading volume of 44,857 shares, compared to its average volume of 128,588. Chugai Pharmaceutical has a twelve month low of $14.52 and a twelve month high of $26.00. The company has a 50 day simple moving average of $23.77 and a two-hundred day simple moving average of $20.37.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.